ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
July 17, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
June 20, 2024 08:45 ET
|
ClearPoint Neuro, Inc.
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
June 01, 2024 09:00 ET
|
ClearPoint Neuro, Inc.
Newly Launched ClearPoint Neuro technology - SmartFrame OR and Prism Laser will be on display at ASSFN in Nashville from June 1 - 4
ClearPoint Neuro Reports First Quarter 2024 Results
May 07, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
Q1-2024 Revenue Growth +41%, a Company Record
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
May 02, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
Novel drug delivery research to be presented by ClearPoint Neuro Biologics team at ASGCT 2024 Annual Meeting in Baltimore
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
April 29, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
FDA Clearance of Prism Bone Anchor Accessory will expand use of the ClearPoint Prism® Neuro Laser Therapy to Operating Room
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
April 24, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
First 10 operating room procedures with SmartFrame OR successfully completed. Company expects positive impact to revenue in 2024 due to OR expansion.
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
April 23, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation...
ClearPoint Neuro felicita a su socio AviadoBio por el primer paciente tratado en su ensayo clínico ASPIRE-FTD que evalúa AVB-101 en personas con demencia frontotemporal con mutaciones en el gen GRN
April 17, 2024 15:21 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, California, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (la «empresa»), una compañía global de dispositivos, células y terapia génica que ofrece navegación...
ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
April 17, 2024 15:21 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalifornien, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (das „Unternehmen“), ein globales Unternehmen für Geräte, Zellen und Gentherapie, das präzise...